Serum cystatin C is associated with kidney function but not with cardiovascular risk factors or subclinical atherosclerosis in patients with Systemic Lupus Erythematosus

被引:0
作者
Patricia Garcia-Garcia
Raquel Castejon
Pablo Tutor-Ureta
R. A. Silvestre
Susana Mellor-Pita
Carlos Jimenez-Ortiz
Miguel Yebra-Bango
机构
[1] IDIPHIM (Puerta de Hierro University Hospital Research Institute),Systemic Autoimmune Diseases Unit, Internal Medicine
[2] Hospital Universitario Puerta de Hierro Majadahonda,Servicio de Medicina Interna
[3] IDIPHIM,Biochemistry
[4] Hospital Universitario Puerta de Hierro Majadahonda,Neurology Service
[5] IDIPHIM (Puerta de Hierro University Hospital Research Institute),undefined
[6] Hospital Universitario Puerta de Hierro Majadahonda,undefined
[7] IDIPHIM (Puerta de Hierro University Hospital Research Institute),undefined
[8] Hospital Universitario Puerta de Hierro Majadahonda,undefined
来源
Clinical Rheumatology | 2017年 / 36卷
关键词
Cardiovascular risk; Cystatin C; Renal function; Subclinical atherosclerosis; Systemic lupus erythematosus;
D O I
暂无
中图分类号
学科分类号
摘要
Cystatin C (CysC) is a protein considered as an excellent marker of renal function, and it has been suggested as an independent predictor of cardiovascular (CV) risk. We evaluated the association of serum CysC with renal function, CV risk factors, inflammation, and subclinical atherosclerosis in Systemic Lupus Erythematosus (SLE) patients. Sixty-one SLE female patients were selected according to estimated glomerular filtration rate (GFR) > 60 ml/min/1.73m2. Renal function parameters, SLE specific factors, CV risk factors, and inflammatory markers were assessed. Subclinical atherosclerosis was assessed by measuring the carotid-femoral pulse wave velocity (PWV) by Doppler velocimetry. Serum CysC concentration was measured using a particle-enhanced immunonephelometric assay that established 0.59–1.01 mg/l as reference values. Patients with high CysC showed significantly altered creatinine, microalbuminuria, and GFR in addition to a significant higher presence of traditional CV risk factors such as arterial hypertension (p < 0.001), metabolic syndrome (p < 0.001), hypertrigliceridemia (p < 0.001), tobacco habit (p < 0.05), and a strong association with arterial stiffness (p = 0.017). Positive correlation between CysC, homocysteine (r = 0.511; p < 0.001) and fibrinogen levels (r = 0.304; p < 0.02) were also observed. A significantly higher SLICC/ACR score was related to high CysC level (p = 0.011), together with higher endothelin-1 and lower TNF serum concentration (p < 0.005). Considering only patients without any renal impairment (microalbumin/creatinine <30 mg/g), no association between CysC level and CV risk factors, arterial stiffness, or SLE-related factors was found. Serum CysC is a good marker of renal function in SLE patients, but it is not independently associated with cardiovascular risk factor or subclinical atherosclerosis.
引用
收藏
页码:2709 / 2717
页数:8
相关论文
共 222 条
  • [1] Manzi S(1997)Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with Framingham study Am J Epidemiol 145 408-415
  • [2] Meilahn E(2005)“Not only … but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus Rheumatology 44 1492-1502
  • [3] Rairie J(2003)Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus New Engl J Med 349 2399-2406
  • [4] Conte CG(2016)Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with systemic lupus erythematosus J Clin Rheumatol 22 8-12
  • [5] Medsger TA(2010)Prediction of cardiovascular events and all-cause mortality with arterial stiffness J Am Coll Cardiol 55 1318-1327
  • [6] Jansen-McWilliams L(2008)Cystatin C—a paradigm of evidence based laboratory medicine Clin Biochem Rev 29 47-62
  • [7] D'Agostino RB(2002)Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis Am J Kidney Dis 40 221-226
  • [8] Kuller LH(2012)Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction Am J Cardiol 109 1431-1438
  • [9] Bruce IN(2007)Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the heart and soul study Circulation 115 173-179
  • [10] Roman M(2006)Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease Ann Intern Med 145 237-246